DOCSLIB.ORG

APPENDIX 1: Search Strategy on Pubmed Identified

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
APPENDIX 1: Search Strategy on Pubmed Identified Revista Panamericana de Salud Pública/Pan American Journal of Public Health Supplementary material to: Brocard E, Reveiz L, Regnaux JP, Abdala V, Ramon Pardo P, Del Rio Bueno A. Antibiotic Prophylaxis for Surgical Procedures: a scoping review. Rev Panam Salud Publica. 2021;45:e62. https://doi.org/10.26633/RPSP.2021.62 This material is part of the original submission and has been submitted to arbitration. It is published without editing as it has been sent by the authors APPENDIX 1: Search Strategy on PubMed identified (("Antibiotic Prophylaxis"[MJ] OR ("Antibiotic Prophylaxis"[TI] OR "Antibiotic Premedication"[TI] OR "Antibiotic Premedications"[TI]) OR (("Anti-Infective Agents"[MJ] OR "Anti-Bacterial Agents"[MJ] OR antibiotic* OR alamethicin* OR amdinocillin* OR (amdinocillin pivoxil*) OR amikacin* OR amoxicillin* OR ("amoxicillin-potassium" clavulanate) OR amphotericin* OR ampicillin* OR anisomycin* OR antimycin* OR aurodox* OR azithromycin* OR azlocillin* OR aztreonam* OR bacitracin* OR bacteriocin* OR bambermycin* OR (bongkrekic acid*) OR brefeldin* OR (butirosin sulfate*) OR calcimycin* OR candicidin* OR capreomycin* OR carbenicillin* OR carfecillin* OR cefaclor* OR cefadroxil* OR cefamandole* OR cefatrizine* OR cefazolin* OR cefixime* OR cefmenoxime* OR cefmetazole* OR cefonicid* OR cefoperazone* OR cefotaxime* OR cefotetan* OR cefotiam* OR cefoxitin* OR cefsulodin* OR ceftazidime* OR ceftizoxime* OR ceftriaxone* OR cefuroxime* OR cephacetrile* OR cephalexin* OR cephaloglycin* OR cephaloridine* OR cephalosporin* OR cephalothin* OR cephamycin* OR cephapirin* OR cephradine* OR chloramphenicol* OR chlortetracycline* OR citrinin* OR clarithromycin* OR (clavulanic acid*) OR clindamycin* OR cloxacillin* OR colistin* OR cyclacillin* OR dactinomycin* OR daptomycin* OR demeclocycline* OR dibekacin* OR dicloxacillin* OR (dihydrostreptomycin sulfate*) OR diketopiperazine* OR distamycin* OR doxycycline* OR echinomycin* OR edeine* OR enviomycin* OR erythromycin* OR filipin* OR floxacillin* OR fluoroquinolone* OR fosfomycin* OR framycetin* OR (fusidic acid*) OR gentamicin* OR gramicidin* OR hygromycin* OR imipenem* OR josamycin* OR kanamycin* OR kitasamycin* OR lactam* OR lasalocid* OR leucomycin* OR lincomycin* OR lincosamide* OR lucensomycin* OR lymecycline* OR mepartricin* OR methacycline* OR methicillin* OR mezlocillin* OR mikamycin* OR minocycline* OR miocamycin* OR moxalactam* OR mupirocin* OR mycobacillin* OR nafcillin* OR natamycin* OR nebramycin* OR neomycin* OR netilmicin* OR netropsin* OR nigericin* OR nisin* OR norfloxacin* OR novobiocin* OR nystatin* OR ofloxacin* OR oleandomycin* OR oligomycin* OR oxacillin* OR oxytetracycline* OR paromomycin* OR (penicillanic acid*) OR (penicillic acid*) OR penicillin* OR piperacillin* OR pivampicillin* OR polymyxin b* OR polymyxin* OR pristinamycin* OR prodigiosin* OR ribostamycin* OR rifabutin* OR rifamycin* OR ristocetin* OR rolitetracycline* OR roxarsone* OR roxithromycin* OR rutamycin* OR sirolimu* OR sisomicin* OR spectinomycin* OR spiramycin* OR streptogramin** OR streptomycin* OR streptovaricin* OR sulbactam* OR sulbenicillin* OR sulfamerazine* OR sulfamethoxypyridazine* OR talampicillin* OR teicoplanin* OR tetracycline* OR thiamphenicol* OR thienamycin* OR thiostrepton* OR ticarcillin* OR tobramycin* OR troleandomycin* OR tunicamycin* OR tylosin* OR tyrocidine* OR tyrothricin* OR valinomycin* OR vancomycin* OR vernamycin* OR viomycin* OR virginiamycin* OR "beta-lactams") AND (Prophylaxis OR prevention OR premedication OR prophylactic*)) AND (surgery[CT] OR "Surgical Procedures, Operative" OR "Ghost Surgery" OR "Operative Procedure" OR "Operative Procedures" OR "Operative Surgical Procedure" OR "Operative Surgical Procedures" OR "Procedure, Operative" OR "Procedure, Operative Surgical" OR "Procedures, Operative" OR "Procedures, Operative Surgical" OR "Surgery, Ghost" OR "Surgical Procedure, Operative" OR E04*[MH] OR "non-surgical"[TI] OR "non surgical"[TI] OR "Non-surgical procedure" OR "non-operative procedure" OR "Non-surgical procedures" OR "non-operative procedures")) NOT ("Periodontal Diseases"[MH] OR "Surgery, oral"[MH] OR dentistry[MH] OR "Surgery, Oral" OR Exodontics OR "Maxillofacial Surgery" OR "Oral Surgery" OR "Surgery, Maxillofacial APPENDIX 2: Quality assessment scores of the included systematic review, from lowest to highest. Study ID AMSTAR 2 score Carney et al. 2018 Critically Low quality score Blood et al. 2017 Critically Low quality score Ghobrial et al. 2015 Critically Low quality score Fernicola et al. 2020 Critically Low quality score Cussans et al. 2016 Critically Low quality score La Regina et al. 2020 Critically Low quality score Foster et al. 2018 Critically Low quality score Soteropulos et al. 2019 Critically Low quality score Abraham et al. 2017 Critically Low quality score Vijendren et al. 2019 Critically Low quality score Hussain et al. 2018 Critically Low quality score Al-Abduljabbar et al. 2017 Critically Low quality score Jaworski et al. 2019 Critically Low quality score Gouvêa et al. 2015 Critically Low quality score Mocanu et al. 2019 Critically Low quality score Mayne et al. 2018 Low quality score King et al. 2018 Low quality score Shao et al. 2019 Low quality score Tanner et al. 2015 Low quality score Song et al. 2016 Low quality score Vander Poorten et al. 2020 Low quality score Moldovan et al. 2019 Low quality score Huang et al. 2016 Low quality score Xu et al. 2016 Low quality score Di Spiezio et al. 2016 Low quality score Gandra et al. 2018 Low quality score Weiss et al. 2019 Low quality score Tan et al. 2020 Low quality score Nguyen et al. 2016 Low quality score Hajibandeh et al. 2019 Moderate quality score Erdas et al. 2016 Moderate quality score Thornley et al. 2015 Moderate quality score Yao et al. 2018 Moderate quality score Sanders et al. 2019 Moderate quality score Sadigursky et al. 2019 Moderate quality score Modha et al. 2018 Moderate quality score Morgenstern et al. 2018 Moderate quality score Musters et al. 2015 Moderate quality score Yang et al. 2016 Moderate quality score Noreikaite et al. 2018 Moderate quality score Carey et al. 2015 Moderate quality score Kim et al. 2018 Moderate quality score Liang et al. 2016 Moderate quality score Alrammaal et al. 2019 Moderate quality score Liu et al. 2019 Moderate quality score Carter et al. 2017 Moderate quality score Guo et al. 2019 Moderate quality score Lynch et al. 2018 Moderate quality score Loggini et al. 2020 Moderate quality score Nuyen et al. 2019 Moderate quality score Kessel et al. 2015 Moderate quality score Texakalidis et al. 2019 Moderate quality score Ramos et al. 2016 Moderate quality score de Jonge et al. 2017 Moderate quality score Purba et al. 2018 Moderate quality score Baltodano et al. 2019 Moderate quality score Voigt et al. 2016 High quality score Sousa et al. 2019 High quality score Siddiqi et al. 2019 High quality score Zhang et al. 2019 High quality score Peng et al. 2019 High quality score Joaquim et al. 2019 High quality score Zeng et al. 2019 High quality score Brand et al. 2019 High quality score Matsui et al. 2018 High quality score Boonchan et al. 2017 High quality score Almeida et al. 2015 High quality score Bollig et al. 2018 High quality score Nabhan et al. 2016 High quality score Gallagher et al. 2019 High quality score Zapata-Copete et al. 2017 High quality score Ayeleke et al. 2017 High quality score Pop-Vicas et al. 2019 High quality score Habib et al. 2019 High quality score Bowen et al. 2018 High quality score Gower et al. 2017 High quality score Bokhari et al. 2019 High quality score Alotaibi et al. 2016 High quality score Liu et al. 2017 High quality score Guo et al. 2019 High quality score Srisung et al. 2017 High quality score Liu et al. 2018 High quality score López-Cano et al. 2019 High quality score APPENDIX 3: Detailed summary of systematic reviews characteristics (study design, surgical procedure, antibiotics reported) and their key findings. Study ID Study Design Surgical Procedure Antibiotics reported Key findings for Primary Outcomes Thornley P, Evaniew N, Riediger M, Winemaker M, Bhandari M, Ghert M. Postoperative Systematic review and Meta-analysis Total joint arthroplasty Nafcillin or cefazolin, teicoplanin, cefuroxime SSI incidence higher (3.1%) of the 2055 patients given postoperative antibiotic prophylaxis and in 45 (2.3%) of the 1981 in the no-treatment group. Non statistically significant findings on antibiotic prophylaxis in total hip and knee arthroplasty: a systematic review and meta- postoperative antibiotic prophylaxis for reduction of SSI rates (risk difference 0.01, 95% CI 0.00 to 0.02; heterogeneity I2 = 26%). analysis of randomized controlled trials. CMAJ Open. 2015;3(3): E338-E343. Voigt, J., Mosier, M. & Darouiche, R. Antibiotics and antiseptics for preventing infection Systematic review and Meta-analysis Total joint arthroplasty 1st vs. 2nd generation cephalosporin, mupirocin Statistically significant findings comparing vancomycin impregnated cement + IV cefazolin to IV cefazolin in revision TKA procedures (P = 0.0129). Non-significant findings on the 1 year in people receiving revision total hip and knee prostheses: a systematic review of outcome of infection when comparing 1st generation vs. 2nd generation cephalosporins in TKA revision (RR = 0.29; 95% CI: 0.01 to 6.95; P = 0.45). Non-significant findings for the comparison randomized controlled trials. BMC Infect Dis 2016; 16, 749. https://doi. mupirocin vs. povidone iodine (PI) on the outcome of infection at 30 days for either revision THA or revision
Load more

Recommended publications
  • Derivatives of Clavulanic Acid, Process for Their Preparation And
    Europaisches Patentamt © ê European Patent Office © Publication number: 0 003 254 Office européen des brevets Bl © EUROPEAN PATENT SPECIFICATION (45) Date of publication of patent spécification: 28.03.84 © Int. ci.3: C 07 D 498/04, A 61 K 31/42, @ Application number: 78300762.8 A 61 K 31/43, @ Date offiling: 07.12.78 A 61 K 31/545 //(C07D498/04, 263/00, 205/00), (A6 1 K3 1 /43, 3 1/42), (A61K3 1/545, 31/42) (54) Derivatives of clavulanic acid, process for their préparation and compositions containing them. (§) Priority: 26.01 .78 GB 312978 @ Proprietor: BEECHAM GROUP PLC Beecham House Great West Road Brentford Middlesex (GB) (43) Date of publication of application: 08.08.79 Bulletin 79/1 6 @ Inventor: Gasson, Brian Charles 9, Clarence Walk (45) Publication of the grant of the patent: Redhill Surrey (GB) 28.03.84 Bulletin 84/13 © Représentative: Hesketh, Alan, Dr. et al, (84) Designated Contracting States: European Patent Attorney Beecham BE CH DEFRGBITNL Pharmaceuticals Great Burgh Yew Tree Bottom Road Epsom, Surrey, KT18 5XQ (GB) (56) Références cited: BE - A - 847 046 The file contains technical information submitted after the application was filed and not included in this spécification Note: Within nine months from the publication of the mention of the grant of the European patent, any person may give notice to the European Patent Office of opposition to the European patent granted. Notice of opposition shall be filed in a written reasoned statement. It shall not be deemed to have been filed until the opposition fee has been paid.
    [Show full text]
  • 28912 Oxoid FDA Cartridge Tables:1
    * Adapted in part from CLSI document M100-S23 (M02-A11) : “Disc diffusion supplemental tablesʼʼ Performance standards for antimicrobial susceptibility testing. The complete standard may be obtained from the Clinical and Laboratory Standards Institute, 940 West Valley Road, Suite 1400, Wayne, PA 19807. Test Cultures (zone diameters in mm) Antimicrobial Agent Disc Code Potency Resistant Intermediate Susceptible Amikacin AK 30 μg EnterobacteriaceaeK, P. aeruginosa, Acinetobacter spp., and Staphylococcus spp. ≤14 15-16 ≥17 Amoxycillin - Clavulanic Acid AMC 20/10 μg EnterobacteriaceaeE ≤13 14-17 ≥18 Staphylococcus spp.A,Q ≤19 — ≥20 Haemophilus spp.A,Y ≤19 — ≥20 AmpicillinC,n AMP 10 μg EnterobacteriaceaeE and Vibrio choleraef ≤13 14-16 ≥17 Staphylococcus spp.A,Q ≤28 — ≥29 Enterococcus spp.A,V,W,k,m ≤16 — ≥17 Haemophilus spp.Y ≤18 19-21 ≥22 Streptococcus spp. ß-Hemolytic GroupA,d — — ≥24 Ampicillin – Sulbactam SAM 10/10 μg EnterobacteriaceaeE, Acinetobacter spp., and Staphylococcus spp. ≤11 12-14 ≥15 Haemophilus spp.A,Y ≤19 — ≥20 Azithromycin AZM 15 μg Staphylococcus spp., Streptococcus spp Viridans Groupn, ß-Hemolytic Group, and S. pneumoniae) ≤13 14-17 ≥18 Neisseria meningitidisA,i — — ≥20 Haemophilus spp.A — — ≥12 Aztreonam ATM 30 μg EnterobacteriaceaeE ≤17 18-20 ≤21 P. aeruginosa ≤15 16-21 ≥22 Haemophilus spp.A — — ≥26 CAR 100 μg Carbenicillin Enterobacteriaceae ≤19 20-22 ≥23 Pseudomonas aeruginosaP ≤13 14-16 ≥17 CEC 30 μg Cefaclor Enterobacteriaceae and Staphylococcus spp. ≤14 15-17 ≥18 Haemophilus spp.Y ≤16 17-19 ≥20 MA 30 μg Cefamandole EnterobacteriaceaeD,E and Staphylococcus spp. ≤14 15-17 ≥18 CefazolinG KZ 30 μg Staphylococcus spp.
    [Show full text]
  • Download Download
    VOLUME 7 NOMOR 2 DESEMBER 2020 ISSN 2548 – 611X JURNAL BIOTEKNOLOGI & BIOSAINS INDONESIA Homepage Jurnal: http://ejurnal.bppt.go.id/index.php/JBBI IN SILICO STUDY OF CEPHALOSPORIN DERIVATIVES TO INHIBIT THE ACTIONS OF Pseudomonas aeruginosa Studi In Silico Senyawa Turunan Sefalosporin dalam Menghambat Aktivitas Bakteri Pseudomonas aeruginosa Saly Amaliacahya Aprilian*, Firdayani, Susi Kusumaningrum Pusat Teknologi Farmasi dan Medika, BPPT, Gedung LAPTIAB 610-612 Kawasan Puspiptek, Setu, Tangerang Selatan, Banten 15314 *Email: [email protected] ABSTRAK Infeksi yang diakibatkan oleh bakteri gram-negatif, seperti Pseudomonas aeruginosa telah menyebar luas di seluruh dunia. Hal ini menjadi ancaman terhadap kesehatan masyarakat karena merupakan bakteri yang multi-drug resistance dan sulit diobati. Oleh karena itu, pentingnya pengembangan agen antimikroba untuk mengobati infeksi semakin meningkat dan salah satu yang saat ini banyak dikembangkan adalah senyawa turunan sefalosporin. Penelitian ini melakukan studi mengenai interaksi tiga dimensi (3D) antara antibiotik dari senyawa turunan Sefalosporin dengan penicillin-binding proteins (PBPs) pada P. aeruginosa. Tujuan dari penelitian ini adalah untuk mengklarifikasi bahwa agen antimikroba yang berasal dari senyawa turunan sefalosporin efektif untuk menghambat aktivitas bakteri P. aeruginosa. Struktur PBPs didapatkan dari Protein Data Bank (PDB ID: 5DF9). Sketsa struktur turunan sefalosporin digambar menggunakan Marvins Sketch. Kemudian, studi mengenai interaksi antara antibiotik dan PBPs dilakukan menggunakan program Mollegro Virtual Docker 6.0. Hasil yang didapatkan yaitu nilai rerank score terendah dari kelima generasi sefalosporin, di antaranya sefalotin (-116.306), sefotetan (-133.605), sefoperazon (-160.805), sefpirom (- 144.045), dan seftarolin fosamil (-146.398). Keywords: antibiotik, penicillin-binding proteins, P. aeruginosa, sefalosporin, studi interaksi ABSTRACT Infections caused by gram-negative bacteria, such as Pseudomonas aeruginosa, have been spreading worldwide.
    [Show full text]
  • 12. What's Really New in Antibiotic Therapy Print
    What’s really new in antibiotic therapy? Martin J. Hug Freiburg University Medical Center EAHP Academy Seminars 20-21 September 2019 Newsweek, May 24-31 2019 Disclosures There are no conflicts of interest to declare EAHP Academy Seminars 20-21 September 2019 Antiinfectives and Resistance EAHP Academy Seminars 20-21 September 2019 Resistance of Klebsiella pneumoniae to Pip.-Taz. olates) EAHP Academy Seminars 20-21 September 2019 https://resistancemap.cddep.org/AntibioticResistance.php Multiresistant Pseudomonas Aeruginosa Combined resistance against at least three different types of antibiotics, 2017 EAHP Academy Seminars 20-21 September 2019 https://atlas.ecdc.europa.eu/public/index.aspx Distribution of ESBL producing Enterobacteriaceae EAHP Academy Seminars 20-21 September 2019 Rossolini GM. Global threat of Gram-negative antimicrobial resistance. 27th ECCMID, Vienna, 2017, IS07 Priority Pathogens Defined by the World Health Organisation Critical Priority High Priority Medium Priority Acinetobacter baumanii Enterococcus faecium Streptococcus pneumoniae carbapenem-resistant vancomycin-resistant penicillin-non-susceptible Pseudomonas aeruginosa Helicobacter pylori Haemophilus influenzae carbapenem-resistant clarithromycin-resistant ampicillin-resistant Enterobacteriaceae Salmonella species Shigella species carbapenem-resistant fluoroquinolone-resistant fluoroquinolone-resistant Staphylococcus aureus vancomycin or methicillin -resistant Campylobacter species fluoroquinolone-resistant Neisseria gonorrhoae 3rd gen. cephalosporin-resistant
    [Show full text]
  • Prediction of Premature Termination Codon Suppressing Compounds for Treatment of Duchenne Muscular Dystrophy Using Machine Learning
    Prediction of Premature Termination Codon Suppressing Compounds for Treatment of Duchenne Muscular Dystrophy using Machine Learning Kate Wang et al. Supplemental Table S1. Drugs selected by Pharmacophore-based, ML-based and DL- based search in the FDA-approved drugs database Pharmacophore WEKA TF 1-Palmitoyl-2-oleoyl-sn-glycero-3- 5-O-phosphono-alpha-D- (phospho-rac-(1-glycerol)) ribofuranosyl diphosphate Acarbose Amikacin Acetylcarnitine Acetarsol Arbutamine Acetylcholine Adenosine Aldehydo-N-Acetyl-D- Benserazide Acyclovir Glucosamine Bisoprolol Adefovir dipivoxil Alendronic acid Brivudine Alfentanil Alginic acid Cefamandole Alitretinoin alpha-Arbutin Cefdinir Azithromycin Amikacin Cefixime Balsalazide Amiloride Cefonicid Bethanechol Arbutin Ceforanide Bicalutamide Ascorbic acid calcium salt Cefotetan Calcium glubionate Auranofin Ceftibuten Cangrelor Azacitidine Ceftolozane Capecitabine Benserazide Cerivastatin Carbamoylcholine Besifloxacin Chlortetracycline Carisoprodol beta-L-fructofuranose Cilastatin Chlorobutanol Bictegravir Citicoline Cidofovir Bismuth subgallate Cladribine Clodronic acid Bleomycin Clarithromycin Colistimethate Bortezomib Clindamycin Cyclandelate Bromotheophylline Clofarabine Dexpanthenol Calcium threonate Cromoglicic acid Edoxudine Capecitabine Demeclocycline Elbasvir Capreomycin Diaminopropanol tetraacetic acid Erdosteine Carbidopa Diazolidinylurea Ethchlorvynol Carbocisteine Dibekacin Ethinamate Carboplatin Dinoprostone Famotidine Cefotetan Dipyridamole Fidaxomicin Chlormerodrin Doripenem Flavin adenine dinucleotide
    [Show full text]
  • Infant Antibiotic Exposure Search EMBASE 1. Exp Antibiotic Agent/ 2
    Infant Antibiotic Exposure Search EMBASE 1. exp antibiotic agent/ 2. (Acedapsone or Alamethicin or Amdinocillin or Amdinocillin Pivoxil or Amikacin or Aminosalicylic Acid or Amoxicillin or Amoxicillin-Potassium Clavulanate Combination or Amphotericin B or Ampicillin or Anisomycin or Antimycin A or Arsphenamine or Aurodox or Azithromycin or Azlocillin or Aztreonam or Bacitracin or Bacteriocins or Bambermycins or beta-Lactams or Bongkrekic Acid or Brefeldin A or Butirosin Sulfate or Calcimycin or Candicidin or Capreomycin or Carbenicillin or Carfecillin or Cefaclor or Cefadroxil or Cefamandole or Cefatrizine or Cefazolin or Cefixime or Cefmenoxime or Cefmetazole or Cefonicid or Cefoperazone or Cefotaxime or Cefotetan or Cefotiam or Cefoxitin or Cefsulodin or Ceftazidime or Ceftizoxime or Ceftriaxone or Cefuroxime or Cephacetrile or Cephalexin or Cephaloglycin or Cephaloridine or Cephalosporins or Cephalothin or Cephamycins or Cephapirin or Cephradine or Chloramphenicol or Chlortetracycline or Ciprofloxacin or Citrinin or Clarithromycin or Clavulanic Acid or Clavulanic Acids or clindamycin or Clofazimine or Cloxacillin or Colistin or Cyclacillin or Cycloserine or Dactinomycin or Dapsone or Daptomycin or Demeclocycline or Diarylquinolines or Dibekacin or Dicloxacillin or Dihydrostreptomycin Sulfate or Diketopiperazines or Distamycins or Doxycycline or Echinomycin or Edeine or Enoxacin or Enviomycin or Erythromycin or Erythromycin Estolate or Erythromycin Ethylsuccinate or Ethambutol or Ethionamide or Filipin or Floxacillin or Fluoroquinolones
    [Show full text]
  • Choline Esters As Absorption-Enhancing Agents for Drug Delivery Through Mucous Membranes of the Nasal, Buccal, Sublingual and Vaginal Cavities
    J|A Europaisches Patentamt 0 214 ® ^KUw ^uroPean Patent O^ice (fl) Publication number: 898 Office europeen des brevets A2 © EUROPEAN PATENT APPLICATION @ Application number: 86401812.2 (3) Int. CI.4: A 61 K 47/00 @ Date of filing: 13.08.86 @ Priority: 16.08.85 US 766377 © Applicant: MERCK & CO. INC. 126, East Lincoln Avenue P.O. Box 2000 @ Date of publication of application : Rahway New Jersey 07065 (US) 18.03.87 Bulletin 87/12 @ Inventor: Alexander, Jose @ Designated Contracting States : 2909 Westdale Court CH DE FR GB IT LI NL Lawrence Kansas 66044 (US) Repta, A.J. Route 6, Box 100N Lawrence Kansas 66046 (US) Fix, Joseph A. 824 Mississippi Lawrence Kansas 66044 (US) @ Representative: Ahner, Francis et al CABINET REGIMBEAU 26, avenue Kleber F-75116 Paris (FR) |j) Choline esters as absorption-enhancing agents for drug delivery through mucous membranes of the nasal, buccal, sublingual and vaginal cavities. @ Choline esters are used as drug absorption enhancing agents for drugs which are poorly absorbed from the nasal, oral, and vaginal cavities. ! r ■ i ■ I njndesdruckerei Berlin 0 214 898 Description CHOLINE ESTERS AS ABSORPTION-ENHANCING AGENTS FOR DRUG DELIVERY THROUGH MUCOUS MEMBRANES OF THE NASAL, BUCCAL, SUBLINGUAL AND VAGINAL CAVITIES 5 BACKGROUND OF THE INVENTION The invention relates to a novel method and compositions for enhancing absorption of drugs from the nasal, buccal, sublingual and vaginal cavities by incorporating therein a choline ester absorption enhancing agent. The use of choline esters to promote nasal, buccal, sublingual and vaginal drug delivery offers several advantages over attempts to increase drug absorption from the gastrointestinal tract.
    [Show full text]
  • Pharmaceutical Microbiology Table of Contents
    TM Pharmaceutical Microbiology Table of Contents Pharmaceutical Microbiology ������������������������������������������������������������������������������������������������������������������������ 1 Strains specified by official microbial assays ������������������������������������������������������������������������������������������������ 2 United States Pharmacopeia (USP) �������������������������������������������������������������������������������������������������������������������������������������������2 European Pharmacopeia (EP) Edition 8�1 ���������������������������������������������������������������������������������������������������������������������������������5 Japanese Pharmacopeia (JP) ������������������������������������������������������������������������������������������������������������������������������������������������������7 Strains listed by genus and species �������������������������������������������������������������������������������������������������������������10 ATCC provides research and development tools and reagents as well as related biological material management services, consistent with its mission: to acquire, authenticate, preserve, develop, and distribute standard reference THE ESSENTIALS microorganisms, cell lines, and related materials for research in the life sciences� OF LIFE SCIENCE For over 85 years, ATCC has been a leading authenticate and further develop products provider of high-quality biological materials and services essential to the needs of basic and standards to the life
    [Show full text]
  • 595 PART 441—PENEM ANTIBIOTIC DRUGS Subpart A—Bulk Drugs
    Food and Drug Administration, HHS § 441.20a (6) pH. Proceed as directed in § 436.202 imipenem per milliliter at 25 °C is ¶85° of this chapter, using an aqueous solu- to ¶95° on an anhydrous basis. tion containing 60 milligrams per mil- (vi) It gives a positive identity test. liliter. (vii) It is crystalline. (7) Penicillin G content. Proceed as di- (2) Labeling. It shall be labeled in ac- rected in § 436.316 of this chapter. cordance with the requirements of (8) Crystallinity. Proceed as directed § 432.5 of this chapter. in § 436.203(a) of this chapter. (3) Requests for certification; samples. (9) Heat stability. Proceed as directed In addition to complying with the re- in § 436.214 of this chapter. quirements of § 431.1 of this chapter, [42 FR 59873, Nov. 22, 1977; 43 FR 2393, Jan. 17, each such request shall contain: 1978, as amended at 45 FR 22922, Apr. 4, 1980; (i) Results of tests and assays on the 50 FR 19918, 19919, May 13, 1985] batch for potency, sterility, pyrogens, loss on drying, specific rotation, iden- PART 441ÐPENEM ANTIBIOTIC tity, and crystallinity. DRUGS (ii) Samples, if required by the Direc- tor, Center for Drug Evaluation and Subpart AÐBulk Drugs Research: (a) For all tests except sterility: 10 Sec. 441.20a Sterile imipenem monohydrate. packages, each containing approxi- mately 500 milligrams. Subpart BÐ[Reserved] (b) For sterility testing: 20 packages, each containing equal portions of ap- Subpart CÐInjectable Dosage Forms proximately 300 milligrams. 441.220 Imipenem monohydrate-cilastatin (b) Tests and methods of assayÐ(1) Po- sodium injectable dosage forms.
    [Show full text]
  • Antibiotic Resistance in Plant-Pathogenic Bacteria
    PY56CH08-Sundin ARI 23 May 2018 12:16 Annual Review of Phytopathology Antibiotic Resistance in Plant-Pathogenic Bacteria George W. Sundin1 and Nian Wang2 1Department of Plant, Soil, and Microbial Sciences, Michigan State University, East Lansing, Michigan 48824, USA; email: [email protected] 2Citrus Research and Education Center, Department of Microbiology and Cell Science, Institute of Food and Agricultural Sciences, University of Florida, Lake Alfred, Florida 33850, USA Annu. Rev. Phytopathol. 2018. 56:8.1–8.20 Keywords The Annual Review of Phytopathology is online at kasugamycin, oxytetracycline, streptomycin, resistome phyto.annualreviews.org https://doi.org/10.1146/annurev-phyto-080417- Abstract 045946 Antibiotics have been used for the management of relatively few bacterial Copyright c 2018 by Annual Reviews. plant diseases and are largely restricted to high-value fruit crops because of Access provided by INSEAD on 06/01/18. For personal use only. All rights reserved the expense involved. Antibiotic resistance in plant-pathogenic bacteria has Annu. Rev. Phytopathol. 2018.56. Downloaded from www.annualreviews.org become a problem in pathosystems where these antibiotics have been used for many years. Where the genetic basis for resistance has been examined, antibiotic resistance in plant pathogens has most often evolved through the acquisition of a resistance determinant via horizontal gene transfer. For ex- ample, the strAB streptomycin-resistance genes occur in Erwinia amylovora, Pseudomonas syringae,andXanthomonas campestris, and these genes have pre- sumably been acquired from nonpathogenic epiphytic bacteria colocated on plant hosts under antibiotic selection. We currently lack knowledge of the effect of the microbiome of commensal organisms on the potential of plant pathogens to evolve antibiotic resistance.
    [Show full text]
  • Pharmacokinetic Evaluation of Amoxicillin/Clavulanicacid And
    PHARMACOKINETIC EVALUATION OF AMOXICILLIN/CLAVULANICACID AND ANTACID INTERACTION Anab Fatima B.Pharm, M.Phil.(Pharmaceutics) Thesis submitted for the award of degree of Ph.D In Pharmaceutics DEPARTMENT OF PHARMACEUTICS FACULTY OF PHARMACY UNIVERSITY OF KARACHI. 1 2 In the name of ALLAH The most Beneficient and tha most Merciful………………. ALLAHUMA SALLEY ALA SYEDENA MAULANA MUHAMMEDUN WA ALA AALEHYY WA ASHABHI BARIK WASALLIM WA SALLO ALEHEY SURAT AL-FATIHAH 1. IN THE NAME OF ALLAH,THE MOST GRACIOUS,THE MOST MERCIFUL. 3 2. ALL THE PRAISES AND THANKS BE TO ALLAH,THE LORD OF THE A LAMIN(MANKIND,JINN AND ALL THAT EXIST). 3. THE MOST GRACIOUS,THE MOST MERCIFUL. 4. THE ONLY OWNER(AND THE ONLY RULING JUDGE)OF THE DAY OF RECOMPENSE(THE DAY OF RESURRECTION). 5. YOU(ALONE) WE WORSHIP,AND YOU(ALONE) WE ASK FOR HELP(FOR EACH AND EVERY THING). 6. GUIDE US TO STRAIGHT WAY. 7. THE WAY OF THOSE WHOM YOU HAVE BESTOWED YOUR GRACE,NOT(THE WAY) OF THOSE WHO EARNED YOUR ANGER NOR OF THOSE WHO WENT ASTRAY.(AAMEEN) 4 DEDICATED TO: My beloved Parentral Grand Father(late),Grand Mother(late),Parents and all those persons whose prayers bring me to this stage. ACKNOWLEDGEMENT “If ALLAH assist you, then there is none that can overcome you” (Holy Quran 3:160) All praise to Almighty Allah who gives me strength, confidence and courage to complete the thesis. I am heartiest thankful to my research supervisor Prof.Dr.S.Baqir.S.Naqvi for his valuable guidance, sincere advice, moral support and encouragement throughout the research project.
    [Show full text]
  • Consideration of Antibacterial Medicines As Part Of
    Consideration of antibacterial medicines as part of the revisions to 2019 WHO Model List of Essential Medicines for adults (EML) and Model List of Essential Medicines for children (EMLc) Section 6.2 Antibacterials including Access, Watch and Reserve Lists of antibiotics This summary has been prepared by the Health Technologies and Pharmaceuticals (HTP) programme at the WHO Regional Office for Europe. It is intended to communicate changes to the 2019 WHO Model List of Essential Medicines for adults (EML) and Model List of Essential Medicines for children (EMLc) to national counterparts involved in the evidence-based selection of medicines for inclusion in national essential medicines lists (NEMLs), lists of medicines for inclusion in reimbursement programs, and medicine formularies for use in primary, secondary and tertiary care. This document does not replace the full report of the WHO Expert Committee on Selection and Use of Essential Medicines (see The selection and use of essential medicines: report of the WHO Expert Committee on Selection and Use of Essential Medicines, 2019 (including the 21st WHO Model List of Essential Medicines and the 7th WHO Model List of Essential Medicines for Children). Geneva: World Health Organization; 2019 (WHO Technical Report Series, No. 1021). Licence: CC BY-NC-SA 3.0 IGO: https://apps.who.int/iris/bitstream/handle/10665/330668/9789241210300-eng.pdf?ua=1) and Corrigenda (March 2020) – TRS1021 (https://www.who.int/medicines/publications/essentialmedicines/TRS1021_corrigenda_March2020. pdf?ua=1). Executive summary of the report: https://apps.who.int/iris/bitstream/handle/10665/325773/WHO- MVP-EMP-IAU-2019.05-eng.pdf?ua=1.
    [Show full text]